Local labs are working to develop treatments for neurological disorders, multiple forms of cancer and dozens of rare genetic diseases. But the next potential blockbuster drug to emerge from the Boston area may target a less fearsome condition that nonetheless afflicts 30 million to 40 million Americans: irritable bowel syndrome. Anthony Lembo, HMS associate professor of medicine at Beth Israel Deaconess Medical Center, is quoted.
